PANews reported on February 4th that the X platform announced the winners of its long-form writing competition. Beaverd (@beaverd) won the million-dollar grand PANews reported on February 4th that the X platform announced the winners of its long-form writing competition. Beaverd (@beaverd) won the million-dollar grand

Beaverd wins $1 million prize for long-form writing on X platform.

2026/02/04 09:18
1 min read

PANews reported on February 4th that the X platform announced the winners of its long-form writing competition. Beaverd (@beaverd) won the million-dollar grand prize with his winning article, "Deloitte, a $74 billion cancer that has spread across the United States." The article explores the role of a large government consulting firm in federal and state government IT systems, analyzing contract data, audit findings, and documented system failures. The article garnered 44.71 million views, 29,000 likes, and 7,700 shares.

The Kobeissi Letter won second place with $500,000 for its economic analysis content, providing real-time analysis of global tariffs and geopolitical trade changes, helping millions understand the reasons behind market fluctuations. The Creators' Choice Award of $250,000 went to DAN KOE (@thedankoe) for his insightful perspectives on personal development, helping people cultivate deep focus, prioritize, and build long-term advantages. Honorable mentions were given to Nick Shirley, Josh Wolfe, Kaizen Asiedu, and Ryan Hall, each receiving $100,000.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.